Preclinical efficacy assessment of CDK4/6 inhibitory drugs in aggressive thyroid cancers and evaluation of phosphorylated CDK4 as sensitivity biomarker.
Soutien à la recherche 'Preclinical efficacy assessment of CDK4/6 inhibitory drugs in aggressive thyroid cancers and evaluation of phosphorylated CDK4 as sensitivity biomarker'.
Soutien
90.000 €
Restez informé.e des nouveaux individus ou organisations soutenus
